Huadong Medicine Co., Ltd
000963
株式のランク
#2704
Huadong Medicine Co., Ltd is a leading pharmaceutical enterprise based in... Huadong Medicine Co., Ltd is a leading pharmaceutical enterprise based in China, primarily focused on the creation, production, and distribution of a wide variety of medicinal products. Its extensive product catalog encompasses traditional Chinese patent medicines, immunosuppressive agents, endocrine treatments, digestive system remedies, cancer therapeutics, cardiovascular medications, and antibiotics. The company also supplies medical devices and offers solutions in the field of aesthetic medicine. Noteworthy product lines include gastrointestinal agents and Active Pharmaceutical Ingredients (APIs). Beyond its core pharmaceutical activities, Huadong Medicine is involved in the manufacturing and management of both traditional Chinese and Western raw medicines, prepared formulations, and health supplements. Its operations extend to the wholesale trade of Traditional Chinese Medicine (TCM) ingredients, prepared TCM decoction pieces, and various chemical preparations, complemented by warehousing and logistical services. A significant area of focus for the company is the research, development, manufacturing, and commercialization of aesthetic medicine products. Established in 1993, Huadong Medicine Co., Ltd maintains its corporate headquarters in Hangzhou, China.
株価
$3.89
時価総額
$6.83B
変化（1日）
-2.22%
変化（1年）
-30.58%
国
CN
取引 Huadong Medicine Co., Ltd (000963)
カテゴリー
Healthcare
Huadong Medicine Co., Ltd（000963）の収益
Jun 2026 時点の収益 TTM: $6.59B
Huadong Medicine Co., Ltd の最新の財務報告によると、現在の収益 (TTM) は $6.59B です。2024 年には $5.74B の収益があり、これは 2023 年の $5.74B と比較して 増加 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Huadong Medicine Co., Ltd の収益履歴（2001 ～ 2026）
各年末の収益
| 年 | 収益 | 変化 |
|---|---|---|
| 2026 (TTM) | $6.59B | 5.71% |
| 2025 | $6.23B | 8.57% |
| 2024 | $5.74B | 0.04% |
| 2023 | $5.74B | 4.96% |
| 2022 | $5.47B | 0.54% |
| 2021 | $5.44B | 5.47% |
| 2020 | $5.16B | 1.29% |
| 2019 | $5.09B | 14.19% |
| 2018 | $4.46B | 4.21% |
| 2017 | $4.28B | 17.02% |
| 2016 | $3.66B | 9.25% |
| 2015 | $3.35B | 9.38% |
| 2014 | $3.06B | 10.99% |
| 2013 | $2.76B | 17.88% |
| 2012 | $2.34B | 32.41% |
| 2011 | $1.77B | 29.90% |
| 2010 | $1.36B | 18.60% |
| 2009 | $1.15B | 29.99% |
| 2008 | $881.72M | 32.65% |
| 2007 | $664.70M | 30.76% |
| 2006 | $508.34M | 17.77% |
| 2005 | $431.65M | 23.93% |
| 2004 | $348.31M | 23.94% |
| 2003 | $281.03M | 12.60% |
| 2002 | $249.58M | 9.48% |
| 2001 | $227.97M | 0.00% |
同業他社の収益
| 企業 | 収益 | 収益の差 | 国 |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| $29.24B | 343.74% |
JP
|
|
| - | - |
CH
|
|
| $6.61B | 0.34% |
IN
|
